ClinicalTrials.gov record NCT07793747

Serum Asprosin, Metabolic Syndrome, and Cardiometabolic Risk in Rheumatoid Arthritis

Record copied from ClinicalTrials.gov: Oct 10, 2026AI summaries generated: Sep 6, 2026

Association of Serum Asprosin With Metabolic Syndrome and Cardiometabolic Risk in Patients With Rheumatoid Arthritis

About this page. This page shows the study's official ClinicalTrials.gov record ↗, with added help to make it easier to understand. We explain medical terms, highlight key details in plain language, and suggest questions you may want to ask the study team.

The record is periodically copied from ClinicalTrials.gov and may lag behind changes. AI summaries are checked by software, not a clinician.Read moreShow less

The official record is written by the study sponsor and published on ClinicalTrials.gov. It may not always reflect the latest changes. Before making any decisions, please confirm important information with the study team and your own healthcare team.

Where you see "AI summary", AI was used to create a plain-language explanation and software checked it against the source. It has not been reviewed by a clinician, so it may contain mistakes or leave out important details.

StatusNot yet recruitingThe study has been registered but has not started enrolling. Sites and contacts may not be listed yet.

Study typeObservationalA study in which researchers do not assign participants to a treatment or other intervention. They observe or measure what happens, which may include study visits, tests, questionnaires or a review of medical records.

Age18 years old and older

SexAll

AI summaryWhat this study is about, in plain languageShow ▾Hide ▴

AI-written from the registry record, not the study's own wording. May contain errors or omissions. Check the registry text on this page and the original record ↗ before acting on it.

This observational case-control study compares serum Asprosin levels in three groups: people with rheumatoid arthritis (RA) who have metabolic syndrome, people with RA who do not have metabolic syndrome, and healthy control individuals. Participants have a clinical assessment, RA disease activity scoring (DAS28-ESR), a physical function questionnaire (HAQ), and fasting blood tests including serum Asprosin measured by ELISA. The study looks for links between Asprosin, RA activity, and cardiometabolic risk measures.

What it is studying. Whether serum Asprosin levels differ among RA patients with metabolic syndrome, RA patients without metabolic syndrome, and healthy controls, and how Asprosin relates to RA disease activity and cardiometabolic risk indices.

What the researchers hope to learn. To clarify the role of serum Asprosin in the cardiometabolic complications of rheumatoid arthritis and to assess its association with disease activity and cardiometabolic risk indices.

What this study is about

The study's own summary, as published on ClinicalTrials.gov. Underlined terms have a short explanation.

Rheumatoid arthritis (RA) is a chronic inflammatory autoimmune disease associated with a significantly increased risk of cardiovascular disease and metabolic syndrome (MetS). Asprosin is a recently identified adipokine involved in glucose regulation, insulin resistance, and systemic inflammation, but its role in the cardiometabolic complications of RA remains incompletely understood. The purpose of this case-control study is to evaluate and compare serum Asprosin levels among RA patients with metabolic syndrome, RA patients without metabolic syndrome, and healthy control individuals. The study will also assess the association between serum Asprosin concentrations, RA disease activity (DAS28-ESR), and various cardiometabolic risk indices (including TyG index, Atherogenic Index of Plasma, and Castelli risk indices). Participants will undergo a comprehensive clinical assessment, disease activity scoring, physical function evaluation using the Health Assessment Questionnaire (HAQ), and laboratory investigations including fasting blood tests and serum Asprosin measurement via ELISA. Findings from this study may help clarify the pathophysiological role of Asprosin in RA and improve cardiometabolic risk stratification in affected patients.

Eligibility

The criteria exactly as listed on ClinicalTrials.gov. Only the study team can say whether they apply to you.

Inclusion criteria

Adult patients aged 18 years or older.
Diagnosis of rheumatoid arthritis fulfilling the 2010 ACR/EULAR classification criteria.
Ability and willingness to provide written informed consent.
Healthy controls: Age- and sex-matched individuals without rheumatoid arthritis or systemic inflammatory diseases.

Exclusion criteria

Presence of other autoimmune diseases or overlap syndromes.
Active acute or chronic infectious diseases.
Pregnancy or lactation.
Current malignancy or previous history of malignancy.
Severe hepatic or renal impairment.
Receipt of medications primarily prescribed for weight reduction or agents known to markedly alter lipid or glucose metabolism, other than standard rheumatoid arthritis therapy.

Study description and what participation involves

The registry record has no detailed description beyond the summary above.

AI summaryWhat participation may involve, in plain languageShow ▾Hide ▴

AI-written from the registry record, not the study's own wording. May contain errors or omissions. Check the registry text on this page and the original record ↗ before acting on it.

Participants will attend a clinical assessment that includes medical history, a physical exam, rheumatoid arthritis disease activity scoring (DAS28-ESR), and the Health Assessment Questionnaire (HAQ) for physical function. They will provide fasting blood samples for routine laboratory tests and for measurement of serum Asprosin using a commercial ELISA kit. Study staff will use these clinical data and blood results to compare Asprosin levels and cardiometabolic risk indices across the study groups (RA with metabolic syndrome; RA without metabolic syndrome; healthy controls). The registry record does not specify additional procedures or long-term follow-up.

How the study is structured. An observational, case-control, cross-sectional study. Participants are placed into three groups (RA with metabolic syndrome; RA without metabolic syndrome; healthy controls) and undergo a single set of assessments: clinical evaluation, RA disease activity scoring (DAS28-ESR), the Health Assessment Questionnaire (HAQ), and fasting blood tests with serum Asprosin measured by ELISA.

Questions you could ask

These questions are suggestions for a conversation with the study team or your own clinician, not advice.

The registry lists this study under Rheumatoid Arthritis; Metabolic Syndrome; Cardiovascular Diseases. Does it apply to my diagnosis?
This is an observational study, so the study itself gives no treatment. What would taking part involve for me, and would it change my usual care?
The registry says recruitment has not started. When is it expected to open, and can I register interest now?
No sites are listed on the registry yet. Where will the study take place?
Which of the eligibility criteria would need to be checked with tests before I could join?

More on Marfan syndrome

Clinical trials20 trials listed for Marfan syndromeEvery trial the registry lists for Marfan syndrome, with recruitment status, phase and sites, updated from ClinicalTrials.gov.See all trials →Research updatesWhat changed in Marfan syndrome researchLatest monthly update: September 2026. Includes: After open aortic repair. New research summarized each month in plain language, with links to every source paper.Read the latest update →

Important dates

Study start: October 2026 (estimated)
Primary completion: October 2027 (estimated)
Study completion: November 2027 (estimated)
Target enrollment: 75 participants (estimated)
Last updated on registry: Aug 31, 2026
Data verified: Oct 10, 2026

Sponsor and research team

The lead sponsor funds and oversees the trial. A pharmaceutical or biotech company sponsor typically means the study is testing that company's drug or device; a hospital, university, or government agency usually indicates investigator-initiated or publicly funded research.

Lead sponsor: Assiut University
Principal investigator: Viola Rafaat Shafik Tadros, Resident of Rheumatology, Rehabilitation and Physical medicine
Assiut University

Participating sites

Study locations have not been posted on ClinicalTrials.gov yet. This study is not yet recruiting, so sites may be added when recruitment begins.

Terms used on this page · explanations by MedicalUpdates.ai

written informed consent: The process of explaining a study, including its risks and what participation involves, so that a person can decide freely whether to take part. Consent is usually documented in writing, and a participant can choose to leave the study later.
Inclusion Criteria: The conditions a person must meet to be considered for the study, for example a confirmed diagnosis, an age range or a test result.
Exclusion Criteria: The conditions that rule a person out even if they meet the inclusion criteria, for example other illnesses, certain medicines or pregnancy.

The study record on this page is reproduced from ClinicalTrials.gov, a database of the U.S. National Library of Medicine, where it was submitted by the study sponsor. MedicalUpdates.ai does not own this content, is not affiliated with or endorsed by ClinicalTrials.gov, NIH, or the U.S. Government, and does not verify the record. Plain-language notes, the glossary and the questions above are added by this site; text in the boxes marked "AI summary" was written by an AI model and may contain errors. Registry records change over time. Check the original record for the current version and discuss eligibility or participation with a qualified healthcare professional.

← Back to clinical trials